APA (7th ed.) Citation

Yanagida, S., Kawagishi, H., Saito, M., Hamano, H., Zamami, Y., & Kanda, Y. Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System. Wiley.

Chicago Style (17th ed.) Citation

Yanagida, Shota, Hiroyuki Kawagishi, Mitsuo Saito, Hirofumi Hamano, Yoshito Zamami, and Yasunari Kanda. Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human IPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System. Wiley.

MLA (9th ed.) Citation

Yanagida, Shota, et al. Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human IPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System. Wiley.